Brenetafusp

Drug identity checked against registry records

Also recorded as IMC-F106C

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314Immunocore LtdPhase 3Recruiting2027-10-16Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.